#United States #Chicago #Lung Cancer #Cizzle Bio #CIZ1B

Cizzle Bio's Revolutionary CIZ1B Test for Lung Cancer

Cizzle Bio, Inc. recently revealed amazing potential for its CIZ1B biomarker test aimed at early lung cancer detection, suggesting it could lead to annual savings of up to $518 million for the U.S. Medicare program. This groundbreaking insight comes from a study published in tandem with the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, co-authored by healthcare economist Jennifer Hinkel, M.Sc. Their research revealed that integrating the CIZ1B test into screening protocols for high-risk Medicare populations may significantly lower not just healthcare costs but also the need for unnecessary procedures while enhancing the rate of early-stage lung cancer identification.

The CIZ1B Blood Test: A Boon for Patients

Developed after over 30 years of extensive research at the University of York, the CIZ1B biomarker blood test focuses on the CIZ1 gene variant associated with early-stage lung cancer. It boasts a 95% sensitivity rate for detecting Stage I lung cancer, combined with a Negative Predictive Value (NPV) of 96%. This impressive accuracy makes it capable of identifying lung cancer at its most treatable stage, a vital factor in improving outcomes for patients. The test is slated to launch commercially in U.S. clinical environments soon, as Cizzle Bio eagerly anticipates broader adoption.

As Hinkel explained, "The economic models suggest the CIZ1B test could emerge not only as a clinical breakthrough but also as a significant economic advantage for our healthcare system, particularly when integrated with screenings targeting high-risk Medicare populations. With early diagnoses, we can reduce treatment costs and provide intervention earlier, optimizing lung cancer screening to be more accurate and accessible."

Addressing Healthcare Costs and Screening Participation

Currently, traditional low-dose CT (LDCT) scans are recommended for lung cancer screenings in high-risk individuals. However, participation rates remain alarmingly low, with only 4% to 6% of eligible Medicare beneficiaries opting for the procedure. The new study posits that incorporating the CIZ1B blood test could increase participation by 15%, addressing many barriers associated with LDCT, including accessibility, travel needs, and concerns regarding radiation exposure. This increase in screening participation is especially crucial in underserved populations who typically face even greater challenges when accessing healthcare services.

Hinkel emphasized the importance of rising screening rates: "Greater participation in programs like these is essential for catching lung cancer at earlier, more treatable stages. We've had our struggles attempting to increase these rates through clinician and patient education alone, but obstacles such as transportation and fears about radiation exposure can lead to lower participation, even when the potential benefits of early detection are substantial. The ease and simplicity of a blood test like CIZ1B can dramatically change this landscape."

Minimizing Procedures and Alleviating Patient Anxiety

In a clinical landscape where LDCT often necessitates follow-up procedures like biopsies for visually suspicious nodules (96% of which turn out to be non-cancerous), the CIZ1B test presents a vital opportunity to cut back on unwanted biopsies. By enhancing screening specificity and thereby reducing false positives, the CIZ1B biomarker test improves patient outcomes not only by reducing healthcare expenses but also by alleviating anxiety around unnecessary invasive procedures.

Bill Behnke, the founder and CEO of Cizzle Bio, highlighted the importance of the research findings: "This publication marks a significant milestone for our company. Our mission remains to facilitate early lung cancer detection that is not only more straightforward but also more accurate and accessible. These findings reinforce the position of CIZ1B as a foundational component for lung cancer screening moving forward."

The abstract detailing these findings is accessible online in conjunction with the ASCO 2025 Annual Meeting and can be reviewed at www.asco.org/abstracts.

Cizzle Bio: Leading the Charge in Cancer Diagnostics

Cizzle Bio is a Texas-based biotech firm dedicated to innovating cancer diagnostics through pioneering biomarker-based blood tests, focusing initially on early lung and gastric cancer detection. Their ultimate goal is to enhance patient empowerment, equip healthcare professionals, and foster better outcomes through compassionate, innovative life-saving solutions. The company holds exclusive licensing for the revolutionary CIZ1B test across the U.S., Canada, and the Caribbean, alongside a worldwide exclusive license for the DEX-G2 gastric cancer test. With the impending commercial launch of CIZ1B in the upcoming months, Cizzle Bio is positioned to make a significant impact in healthcare diagnostics by leading the charge in effective cancer detection measures.